272 related articles for article (PubMed ID: 10235026)
1. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
Meerpohl HG
Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
Ozols RF
Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
[TBL] [Abstract][Full Text] [Related]
4. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
5. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
6. Identification of risk factors for requiring transfusion during front-line chemotherapy for ovarian cancer.
Hensley ML; Lebeau D; Leon LF; Venkatraman E; Waltzman R; Sabbatini P; Almadrones L; Chi D; Spriggs D
Gynecol Oncol; 2001 Jun; 81(3):485-9. PubMed ID: 11371143
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
Bolis G; Scarfone G; Villa A; Parazzini F
Gynecol Oncol; 2001 May; 81(2):331-3. PubMed ID: 11330974
[No Abstract] [Full Text] [Related]
8. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer.
Neijt JP; du Bois A
Semin Oncol; 1999 Feb; 26(1 Suppl 2):78-83. PubMed ID: 10190786
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Aravantinos G; Fountzilas G; Bamias A; Grimani I; Rizos S; Kalofonos HP; Skarlos DV; Economopoulos T; Kosmidis PA; Stathopoulos GP; Briasoulis E; Pectasides D; Samantas E; Timotheadou E; Papadimitriou C; Papanikolaou A; Onyenadum A; Papakostas P; Bafaloukos D; Dimopoulos MA;
Eur J Cancer; 2008 Oct; 44(15):2169-77. PubMed ID: 18691879
[TBL] [Abstract][Full Text] [Related]
12. Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Markman M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):88-9. PubMed ID: 7597438
[TBL] [Abstract][Full Text] [Related]
13. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
14. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
[TBL] [Abstract][Full Text] [Related]
15. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions].
Cure H; Dauplat J; Cholet P
Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of advanced ovarian cancer.
McGuire WP; Ozols RF
Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
[TBL] [Abstract][Full Text] [Related]
17. [Latest information in the diagnoses of ovarian carcinoma].
Isonishi S
Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel with carboplatin for the treatment of ovarian cancer.
Neijt JP; Lund B
Semin Oncol; 1996 Dec; 23(6 Suppl 15):2-4. PubMed ID: 8996588
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced ovarian cancer: current status and future directions.
Ozols RF; Vermorken JB
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-1-S2-9. PubMed ID: 9045324
[TBL] [Abstract][Full Text] [Related]
20. Medical treatment of epithelial ovarian cancer.
González-Martín AJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1125-43. PubMed ID: 15606338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]